Home » Market News » DirectorsTalk Highlights » Developing the next generation of cancer therapies
Avacta Group Plc

Developing the next generation of cancer therapies

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current cancer immunotherapies as well as current high off-target toxicity experienced by most patients.

Avacta expects to enter the clinic with its lead pre|CISION™ programme, a tumour activated form of doxorubicin, in the middle of 2020. The lead Affimer® programme, a PD-L1 Affimer® antagonist, will form the basis of future bispecifics, combinations with pre|CISION™ chemotherapies and novel tumour microenvironment activated drug conjugates (TMAC®).

vacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.